Notes to the Consolidated Financial Statements continued 4.
Finance Expense 2018 2017 Underlying m m Finance expense arising from: Financial liabilities at amortised cost 6.8 5.0 Net Interest on net defined benefit obligations 0.1 0.1 Underlying finance expense 6.9 5.1 2018 2017 Non-underlying m m Loss on extinguishment of debt note 21 0.4 Fair value and other movements on deferred and contingent consideration 0.9 0.2 Non-underlying finance income expense 0.5 0.2 Total finance expense 6.4 5.3 5.
Non-underlying Items Non-underlying items charged to operating profit comprise: 2018 2017 m m Amortisation of acquired intangibles classified within selling, general and administrative expenses 46.1 29.0 classified within research and development expenses 8.0 11.4 Impairment of assets available for sale 0.6 Remeasurement of contingent consideration 0.1 Fair value uplift of inventory acquired through business combinations 5.1 4.2 Rationalisation costs 0.8 Expenses relating to acquisition activities 3.1 2.1 Rationalisation of manufacturing organisation 2.9 65.1 48.1 Amortisation of acquired intangibles reflects the amortisation of the fair values of future cash flows recognised on acquisition in relation to the identifiable intangible assets acquired.
The remeasurement of the contingent consideration balance relates to the net credit to the income statement on the reassessment of future milestone and royalty payments on a licensing agreement.
The fair value uplift of inventory acquired through business combinations is recognised in accordance with IFRS 3 Business Combinations to record the inventory acquired at fair value and its subsequent release into the income statement.
Expenses relating to acquisition activities includes legal and professional fees incurred during the acquisitions of AST Farma and Le Vet 2.8 million and Other 0.3 million.
Other is offset with the profit on the sale of human marketing authorisations acquired from previous acquisitions of 0.4 million.
Rationalisation of manufacturing organisation relates to the cost associated with this strategic programme.
Impairment of assets available for sale in the prior year relates to the impairment of the investment in Jaguar Animal Heath Inc. Rationalisation costs relate to the integration and restructuring programmes implemented subsequent to acquisitions.
126 Dechra Pharmaceuticals PLC Annual Report and Accounts for the year ended 30 June 2018 www.
